QIAGEN
Financial Report 2018

  • Delivers on 2018 outlook for sales and exceeds goal for adjusted earnings per share
  • Group net sales rise 6% at constant exchange rates (CER) to $1.50 billion
  • Adjusted operating income at 27% of sales at $403.3 million
  • Adjusted diluted EPS of $1.35 CER per share vs. $1.27 in 2017
  • Free cash flow rises 27% to $249.7 million in 2018
  • Growth in 2018 from dynamic and disruptive Sample to Insight portfolio

Our Mission

As the innovative market and technology leader, QIAGEN creates Sample to Insight solutions that enable access to valuable molecular insights from any biological sample.

Read more

Overview

QIAGEN Insights Magazine

To the magazine

Report of the Supervisory Board

Read more

The Executive Committee

Read more

Common Shares

Read more

Management Report

Business and Operating Environment

Read more

Opportunities and Risks

Read more

Performance Review

Read more

Human Resources

Read more

Non-Financial Statement

Read more

Future Perspectives

Read more

Governance

Corporate Governance and Compensation

Read more

Financial Results

Consolidated Financial Statements

Read more

Notes to Consolidated Financial Statements

Read more

Auditor’s Reports

Read more

List of Subsidiaries

Read more

Appendix

Service

Read more

Downloads

  • Financial Report 2018 – Complete
    14MB PDF
    Download
  • Financial Report 2018 – Overview
    695KB PDF
    Download
  • Financial Report 2018 – Management Report
    7.6MB PDF
    Download
  • Financial Report 2018 – Corporate Governance and Compensation
    1.4MB PDF
    Download
  • Financial Report 2018 – Financial Results
    8.6MB PDF
    Download
  • Financial Report 2018 – Service
    24KB PDF
    Download